Background: Increased mitogen-activated protein kinase (MAPK) signaling, small GTPase activation, cytoskeletal rearrangements, and the directed targeting of proteases to sites of extracellular matrix degradation all accompany the process of tumor cell invasion. Several studies have implicated the small GTP-binding protein ARF6 in tumor cell invasion, although the molecular basis by which ARF6 facilitates this process is unclear. Results: We show that the ARF6 GTP/GDP cycle regulates the release of protease-loaded plasma membrane-derived microvesicles from tumor cells into the surrounding environment. To enable microvesicle shedding, ARF6-GTP-dependent activation of phospholipase D promotes the recruitment of the extracellular signal-regulated kinase (ERK) to the plasma membrane where, in turn, ERK phosphorylates and activates myosin light-chain kinase (MLCK). MLCK-mediated MLC phosphorylation is required for microvesicle release. Inhibition of ARF6 activation is accompanied by PKC-mediated phosphorylation of MLC, which blocks microvesicle shedding. Protein cargo appears to be selectively sorted into microvesicles, and adhesion to the extracellular matrix (ECM) is facilitated by microvesicle-associated integrin receptors. Conclusions: Microvesicle shedding in tumor cells occurs via an actomyosin-based membrane abscission mechanism that is regulated by nucleotide cycling on ARF6. Microvesicle shedding appears to release selected cellular components, particularly those involved in cell adhesion and motility, into the surrounding environment. These findings suggest that ARF6 activation and the proteolytic activities of microvesicles, both of which are thought to correlate directly with tumor progression, could potentially serve as biomarkers for disease.
Introduction
Metastasis, a life-threatening hallmark of cancer, occurs when cells detach from the primary tumor and ''invade'' surrounding tissues to reach distal locations [1] . Growth factor-induced signaling, cytoskeletal rearrangements mediated by the Rhofamily GTPases, and alterations to adhesive and migratory potential of cells all accompany the process of cell invasion [2] . Furthermore, proteases from all four classes (serine, cysteine, aspartic, and metalloproteases) have been implicated in extracellular matrix (ECM) degradation, and their expression, activation, and secretion are vital for tumor cell invasion [3] .
Over the past few years, ARF6, of the ARF family of small GTP-binding proteins, has emerged as an important signaling molecule and has been shown to regulate membrane trafficking and actin cytoskeleton remodeling, both of which can impinge on the acquisition of migratory and/or invasive potential (reviewed in [4] ). Recent studies utilizing in vitro cell invasion assays have indicated that in invasive melanoma, glioma, and breast cancer cell lines, the ARF6 GTP/GDP cycle can regulate invasive potential [4] . Cellular depletion of ARF6 by small interfering RNA (siRNA) or inhibition of ARF6 activation by expression of a dominant-negative ARF6 mutant attenuates tumor cell invasion in vitro. Recent studies in animal models have also revealed a vital role for ARF6 activation in melanoma and glioma cell invasion [5, 6] . Moreover, screening of various breast tumor cell lines reveals a direct correlation between ARF6 protein expression and invasive capacity [7] . Finally, the ARF6 exchange factor GEP100 is expressed in 70% of primary breast ductal carcinomas and is preferentially coexpressed with EGFR in malignant tumors [8] .
What might be the cellular basis by which ARF6 promotes cell invasion? First, ARF6 has been implicated in regulation of invadopodia turnover [4] . Second, via its effects on membrane traffic and remodeling, ARF6 could regulate protease secretion. The current study focuses on the role of ARF6 in protease release. We show that, via its effects on phospholipid metabolism and extracellular signal-regulated kinase (ERK) activation, ARF6 regulates protease release by modulating the shedding of plasma membrane-derived microvesicles into the surrounding environment. Vesicle shedding by the outward fission of membrane vesicles from the cell surface is a selective process that occurs in a spectrum of normal and, more frequently, tumor cells, both in vivo and in vitro [9] . These released microvesicles (also referred to as microparticles, particles, and ectosomes) have been widely detected in various biological fluids including peripheral blood and ascitic fluids; their composition depends on the cells from which they originate [10, 11] . They are thought to facilitate cell invasion, evasion of the immune response, bone mineralization, and even tumor cell intravasation by reducing cell size [12] . Here we provide structural and biochemical characterization of ARF6-positive microvesicles shed by tumor cells. We also show that protease cargo contained within the microvesicles is functionally robust and promotes matrix degradation. Finally, we delineate the pathway by which ARF6 maneuvers the actomyosin machinery to facilitate shedding of microvesicles from the tumor cell surface. These findings are significant particularly in light of reports demonstrating that proteolytic activities of microvesicles shed by tumor cells correlate directly with malignancy and invasiveness [13, 14] .
Results

Phenotypic Variations of LOX ARF6-GDP
and LOX ARF6-GTP Cell Lines To investigate mechanisms by which ARF6 promotes cell invasion, we made use of LOX ARF6-GTP and LOX ARF6-GDP cell lines that stably express either a HA-tagged, GTPase-deficient mutant of ARF6, ARF6-Q67L, or the dominant-negative ARF6 , and LOX ARF6-GDP cells in culture at low confluency were imaged via phase-contrast microscopy. Arrows point to shed vesicles in the growth media of LOX and LOX ARF6-GTP cells. Scale bar represents 10 mm. (C) Vesicles released into the growth media from 2.2 3 10 6 LOX, LOX ARF6-GTP , and LOX ARF6-GDP cells were isolated and probed for ARF6 and b1-integrin by western blotting (left), or protein was quantitated (right). The average of three separate experiments is shown with standard error bars. Cell lysates were probed for ARF6 and a-tubulin by western blotting. Lower-and higher-molecular-weight ARF6 bands in LOX ARF6 cells correspond to endogenous and HA-tagged exogenous ARF6, respectively. (D) LOX ARF6-GTP and LOX ARF6-GDP cells were plated on FITC-gelatin-coated coverslips and allowed to ''invade.'' The cells were fixed and stained for cortactin (blue) and actin (red) (top) or b1-integrin (red) (middle and bottom). Arrows point to invadopodia; arrowheads indicate shed vesicles. Note the arborization phenotype of LOX ARF6-GTP cells when the underlying gelatin is relatively thick (middle). Scale bar represents 10 mm.
mutant, ARF6-T27N, respectively. The most striking phenotype observed upon microscopic examination of LOX ARF6-GDP cells was the presence of vesicle-like bulbous structures that decorated the cell surface ( Figures 1A and 1B) . These structures were also seen on the surfaces of LOX and LOX ARF6-GTP cell lines ( Figures 1A and 1B) , although they were less readily obvious. Instead, in the latter two cell lines, vesicles were released into the growth medium ( Figure 1B) . The lack of vesicles in the growth media of LOX ARF6-GDP cells suggests that ARF6 activation is likely required for their release. When collected by low-speed centrifugation of the growth media and examined for total protein or probed for ARF6 expression, vesicles shed from LOX ARF6-GTP cells exhibited significantly more protein and ARF6, indicative of increased shedding from these cells, relative to the parental cell line ( Figure 1C) . Furthermore, mutant ARF6-GDP was not present on shed vesicles.
The release of vesicles was not as apparent in earlier investigations when LOX cells were seeded on gelatin matrix [15] , presumably because they were released into the matrix at the sites of cell invasion. In addition, their detection could have been hampered as a result of low efficiency of transient transfection used in the previous study. In this study, however, upon careful examination of LOX ARF6-GTP cells on gelatincoated coverslips, we were able to detect the presence of vesicles in the matrix on the cell surface ( Figure 1D ). Furthermore, as shown in Figure 1D , upper panel, these vesicular structures appear to be distinct from cortactin-positive invadopodia that extend into the gelatin matrix. Vesicles do not contain cortactin, although they label for b1-integrin ( Figure 1D ; see also below), which is also present in invadopodia [16] . Quantitation of cortactin label in vesicles relative to invadopodia is shown in Figure S1 available online. Some cells exhibit expansive membrane arbors decorated with microvesicles ( Figure 1D , middle panel). Cells had a tendency to adopt this arborization phenotype, suggestive of horizontal movement when the underlying gelatin is relatively thick (R5 mm). It is possible that cells form invadopodia at the adherent face initially and that when they invade into ''substantial'' matrix and move laterally, this arbor phenotype takes effect. In contrast, LOX ARF6-GDP cells appear bulbous when plated on gelatin, largely because of vesicles studded at the cell surface and little to no matrix degradation underneath the cells (Figure 1D, lower panel) . As reported previously, invadopodia protrusions at the adherent surface were not observed upon expression of the dominant-negative ARF6 mutant [15] . Thus, ARF6 activation is coupled to two apparently distinct cellular processes linked to matrix invasion, invadopodia formation and the release of surface vesicles into the surrounding environment. In this study, we focus on mechanisms underlying ARF6-regulated vesicle shedding from the tumor cell surface.
Morphological examination of LOX ARF6-GTP and LOX ARF6-GDP cell lines via electron microscopy (EM) suggested that vesicles at the surface of cells are heterogeneous in size (300-900 nm) ( Figure 1E ). EM-based investigations also indicated that cells display no signs of nuclear fragmentation or apoptosis. All of the above suggests that the ARF6 GTPase cycle regulates the release of a heterogeneous population of vesicles from tumor cells into the surrounding environment.
We also examined vesicle shedding in other tumor cell lines: SW480, a colon carcinoma cell line; PC3, a prostate adenocarcinoma cell line; and MDA-MB-231, an invasive breast tumor cell line. Gross morphological examination by phase-contrast microscopy showed that shed vesicles were present in the growth media of all aforementioned cell lines (data not shown). Analysis of shed vesicles collected from the growth media by immunoblotting revealed the presence of endogenous ARF6 on isolated vesicles ( Figure 1F ). Furthermore, dominant inhibition of ARF6 function by expression of ARF6-T27N in these tumor cell lines prevented vesicle release (data with SW480 cell line is shown in Figure S2 ).
ARF6-GTP Facilitates the Release of Plasma
Membrane-Derived ''Microvesicles'' into the Surrounding Environment There is accruing evidence for the existence of unconventional secretory mechanisms, such as the release of exosomes and microvesicles that do not utilize the classical signal-peptide secretory transport pathway. Exosomes are internal vesicles of multivesicular bodies and/or late endosomes that are released upon exocytosis [17] . Morphological characterization of ARF6-regulated shed vesicles suggests that they are ''microvesicles,'' and henceforth they are referred to as such. Isolated ARF6-positive vesicles pellet by centrifugation at w10,000 3 g, unlike exosomes, which sediment by centrifugation at w100,000 3 g (Figure 2A ). Figure 2A shows that ARF6-positive vesicles are not present in the 100,000 3 g fraction. Ultrastructural analyses of whole-mount preparations of the 10,000 and 100,000 3 g fractions confirmed the heterogeneity of the 10,000 3 g microvesicles relative to the more uniform 50-70 nm vesicles characteristic of exosomes in the 100,000 3 g fraction ( Figure 2B ).
Studies have shown that phosphatidylserine (PS) externalization accompanies shedding of plasma membrane-derived microvesicles [11] . Indeed, we found externalization of PS on the surface of microvesicles based on reactivity with annexin V, a high-affinity PS-binding protein. This was particularly evident in LOX ARF6-GDP cells where microvesicles stud the cell surface ( Figure 2C ). We also noted that these microvesicles are not apoptotic bodies. As stated above, expression of ARF6 mutants in LOX cells does not induce morphological changes, such as condensed chromatin and pyknotic nuclei, or label for cleaved caspase-3. On the other hand, when treated with okadaic acid, a known inducer for apoptosis, a higher proportion of cells label for cleaved caspase-3 ( Figure 2D ). Thus, ARF6 activation facilitates the release of microvesicles.
Shed Microvesicles Contain Proteases and Facilitate ECM Degradation
Previous reports have shown that microvesicles shed by breast carcinoma and ovarian cancer cell lines contain proteases like MMP-2 and MMP-9 [18] . We found that ARF6-positive microvesicles from the 10,000 3 g fraction contained high-and low-molecular-weight gelatinases, as indicated by gelatin zymography ( Figure 3A ) and MT1MMP ( Figure 4B ). Of note, MT1MMP silencing significantly decreased the basal invasiveness in parental LOX cells (unpublished data). Moreover, shed vesicles, when seeded on FITC-gelatin, were capable of matrix degradation that appeared as dark spots around microvesicle membranes ( Figure 3B ).
It has been proposed that b1-integrins facilitate interaction of shed microvesicles with the ECM and that vesicle contents are released after microvesicle burst induced by acidic pH characteristic of the tumor environment [19] . We found that addition of inactivating b1-integrin antibody AIIB2 to isolated microvesicles ( Figure 3B ) or LOX cells (data not shown) blocked adhesion and matrix degradation, suggesting that protein topology in the microvesicle membrane is still maintained and that integrin receptor association with matrix is important for microvesicle-mediated matrix degradation. AIIB2 also labels the extracellular surface of cells and shed microvesicles ( Figure 3C ). Thus, although proteases at the invadopodia surface facilitate local pericellular proteolysis, microvesicle release could provide a mechanism for rapid and directed proteolysis at distal sites creating paths of less resistance.
Selective Sorting of Cargo into Cell Surface Microvesicles
Besides proteases, microvesicles have been shown to be selectively enriched in b1-integrin receptors and major histocompatibility complex (MHC) class I molecules. Both MHC class I molecules and integrin receptors traffic to and from the plasma membrane via ARF6-regulated endosomal compartments [20] . Figure 3D shows labeling for MHC class I in LOX ARF6-GDP cells in the perinuclear compartments and at the cell surface, but largely at the cell surface in LOX ARF6-GTP cells. ARF6-GTP cells were analyzed by wholemount electron microscopy. Microvesicles isolated in the 10,000 3 g fraction are larger (300-900 nm) and heterogeneous relative to the more uniform 50-70 nm vesicles in the 100,000 3 g fraction typical of exosomes. Scale bar represents 500 nm. Western blotting analysis of shed vesicles revealed that along with endogenous ARF6, MHC-I, b1-integrin, VAMP3, and MT1MMP were also present in microvesicles ( Figure 3E ). Of note, processed forms of MT1MMP are present in the microvesicles. However, microvesicles were devoid of transferrin receptors, which localize to endosomes and the cell surface; Rab8 and VAMP7, which regulate the targeting of MT1MMP to the cell surface; and cortactin and Tks5, which are present in invadopodia. Thus, cargo trafficked via recycling endosomes to the cell surface appears to be selectively sorted into these surface microvesicles.
ARF6-GTP-Induced Microvesicle Shedding Requires ERK ARF6-enhanced melanoma cell invasion is dependent on the activation of ERK [15] . Moreover, the ARF6 GTPase cycle regulates ERK activation [15, 21, 22] downstream of c-Raf [23] . Therefore, we investigated whether ARF6-GTP-induced microvesicle shedding is also dependent on ERK signaling. Treatment of LOX and LOX ARF6-GTP cells with U0126, an inhibitor of MEK, the kinase immediately upstream of ERK, resulted in significant inhibition of basal as well as ARF6-GTP-enhanced microvesicle shedding ( Figure 4A ). Upon MEK inhibition, both parental LOX and LOX ARF6-GTP accumulated microvesicles at the cell surface that resembled the LOX ARF6-GDP phenotype ( Figure 4B) . Similarly, MEK inhibition also blocked microvesicle shedding from PC3 and SW480 cell lines ( Figure S3 ). Thus, ARF6-regulated microvesicle shedding requires ERK.
Consistent with earlier findings in HeLa cells [21] , we found that ERK localizes to the cytoplasm in LOX ARF6-GDP cells (Figure 4C) . In contrast, membrane-associated ERK is predominantly at the cell surface in LOX and LOX ARF6-GTP cells. This becomes further evident in subcellular fractionation studies, wherein the activated phospho-ERK distribution is significantly more in the membrane fraction of LOX ARF6-GTP cells ( Figure 4D ). Thus, ARF6 activation likely enhances ERK redistribution to the plasma membrane, which in turn facilitates its phosphorylation and microvesicle release.
ARF6-Regulated ERK Activation Requires
Phospholipase D Studies have shown that ARF6 simulates phospholipase D (PLD) activity [4] . Further, PLD has been shown to facilitate ERK activation. Here we tested the hypothesis that ARF6-regulated PLD activity is required for ERK activation. First we examined phospho-ERK levels upon PLD inactivation. We found that expression of ARF6-N48I, an ARF6 mutant defective in PLD activation, inhibits ERK activation ( Figure 5A ) and microvesicle shedding ( Figure 5B ). Phosphatidic acid (PA) levels were significantly decreased in ARF6-N48I-expressing cells ( Figure 5C ), and this decrease was accompanied by ERK localization to intracellular cytoplasmic structures (Figure S4) . Next we used primary alcohols to inhibit PLD, which results in the formation of phosphatidyl alcohol at the expense of phosphatidic acid by replacing water. We found that treatment of cells with 1-butanol also inhibits ERK activation (data not shown) and microvesicle shedding (Figure 5D) . Thus, PLD activation is upstream of ERK activation and is essential for ARF6-regulated microvesicle shedding.
Next we investigated whether we could rescue the shedding of microvesicles in LOX ARF6-GDP cells by restoring phospho-ERK levels or by stimulating PLD activity by pathways independent of ARF6. Treatment with propranolol, a PA phosphohydrolase inhibitor [24] , restored phospho-ERK levels in LOX ARF6-GDP cells ( Figure 5E ) and induced microvesicle shedding in LOX ARF6-GDP cells (Figure 5F ). Unlike propranolol, another G protein-coupled receptor antagonist, atenolol, did not have any effect on phospho-ERK levels or microvesicle release ( Figures 5E  and 5F ). These data corroborate the importance of PLD and ERK activation in regulating microvesicle shedding. Finally, we determined the effect of 1-butanol on microvesicle shedding induced by expression of constitutively activated MEK. Activated MEK increases microvesicle shedding more than 12-fold compared to the parental LOX cells; however, 1-butanol had little to no effect on microvesicle shedding, confirming that ERK lies downstream of PLD activation (data not shown).
ERK Facilitates Microvesicle Shedding by Phosphorylating Myosin Light Chain
Treatment of LOX cells with blebbistatin, a small-molecule inhibitor of myosin II activity, or with latrunculin A, an actinbinding toxin that inhibits actin polymerization, profoundly affected the microvesicle release. In the presence of blebbistatin, microvesicles did not form ( Figure 6A ). Eighty-five to ninety percent of latrunculin A-treated cells exhibited clustered microvesicles at the cell surface ( Figure 6A ). Accordingly, latrunculin A treatment also inhibited the release of microvesicles from both parental LOX and LOX ARF6-GTP cells ( Figure 6B ). Thus, vesicle shedding is likely mediated via an actomyosin-dependent mechanism. Myosin light-chain kinase (MLCK), a Ca 2+ /calmodulin-dependent kinase, phosphorylates myosin II light chain (MLC) to promote contraction of the actin-based cytoskeleton [25] . ERK has been shown to phosphorylate MLCK, which in turn phosphorylates MLC at Thr18/Ser19 and thereby stimulates MLC activity [26, 27] . We tested the hypothesis that ARF6-GTP-induced ERK activation at sites of vesicle release leads to localized activation of MLCK, which in turn stimulates serine phosphorylation of MLC to allow force generation required for microvesicle fission. In support of this contention, immunofluorescence labeling of LOX tumor cells revealed that phospho-MLC localizes to the ''necks'' of microvesicles at the cell surface ( Figure 6C ).
We examined phosphorylation of MLC in parental LOX and LOX mutant lines by western blotting. As shown in Figure 6D , levels of phospho-MLC are significantly increased in LOX ARF6-GTP cells compared to parental LOX cells. Treatment of parental LOX and LOX ARF6-GTP cells with ML-7, an MLCK inhibitor, blocks MLC phosphorylation as well as microvesicle shedding ( Figure S5 ). Taken together, these data show that ARF6 facilitates microvesicle fission via a mechanism that involves ERK-dependent MLC phosphorylation.
As seen in Figure 6D , and contrary to our expectations, no decrease in phospho-MLC levels was observed in LOX ARF6-GDP cells, and in fact they were slightly higher than basal levels. A possible explanation for this observation is that the phosphorylation of MLC in LOX ARF6-GDP cells is ''inhibitory'' and independent of ERK. To investigate this further, we compared the levels of phospho-MLC in the presence and absence of U0126 in parental LOX and LOX mutant lines. As seen in Figure 6E , inhibition of phospho-MLC was evident in the presence of MEK inhibitor in parental LOX and in LOX ARF6-GTP cells, but there was no inhibition in phospho-MLC levels in LOX ARF6-GDP cells. Also, treatment with ML7 had little to no effect on MLC phosphorylation in LOX ARF6-GDP cells ( Figure S5 ). This further confirms that the phosphorylation of MLC in LOX ARF6-GDP cells is not mediated by ERK. We examined alternative pathways such as the activation of PKC or p38 [28, 29] for MLC phosphorylation in LOX ARF6-GDP cells. To distinguish between PKC-and p38-mediated phosphorylation of MLC, LOX ARF6-GDP cells were treated with SB203580, a p38 inhibitor, or Go6976, a PKC inhibitor. We found that phospho-MLC levels were decreased specifically upon PKC inhibition ( Figure 6F ). Thus, MLC phosphorylation in LOX ARF6-GDP occurs via PKC and is independent of phospho-ERK. We also noted that MLC phosphorylation is independent of PKC in parental LOX and in LOX ARF6-GTP cells, because no decrease in phospho-MLC levels was observed in the presence of PKC inhibitor ( Figure S4 ). Thus, in LOX ARF6-GDP cells, MLC is phosphorylated by PKC, which is inhibitory, whereas in LOX ARF6-GTP cells, MLC phosphorylation is regulated upstream by ERK, a step that promotes MLC-regulated contraction and, in turn, microvesicle fission (see Figure 7) . Pertinent to these findings is that PKC-mediated MLC phosphorylation has been documented to decrease MLC activity. In this regard, slow stretch of the canine basilar artery is accompanied by the triphosphorylation of myosin light chain (MLC 20 ) at Thr9, Thr18, and Ser19, which results in the inhibition of myogenic contraction and thereby muscle relaxation [30] . In sum, ARF6-GTP facilitates microvesicle fission via a mechanism that involves ERK-dependent MLC phosphorylation, and ARF6-GDP has the opposite effect via PKC-induced phosphorylation of MLC.
Discussion
Microvesicle-mediated release of proteases is an important but understudied area of tumor cell biology. Our studies demonstrate that ARF6 has a critical role in regulating the shedding of microvesicles containing functional proteases. Microvesicle release is dependent on PLD activity, which in turn leads to the activation of ERK. ERK phosphorylates and activates MLCK, a known substrate for phospho-ERK. MLCK, in turn, phosphorylates and activates MLC. This would allow actomyosin-based contraction at the necks of microvesicles, facilitating their release into the extracellular space.
There is mounting evidence that the release of microvesicles serves to facilitate ECM degradation. Most striking in this regard is the reported presence of protease-loaded membrane microvesicles with invasive properties in malignant ovarian ascites derived from women with stage I-IV ovarian cancer [14] . This study also showed that late-stage ascites had significantly more microvesicles than those in early-stage disease, although the invasive ability of the microvesicles was about the same irrespective of the disease stage. These studies assert the physiological relevance and importance of the data described here. Indeed, we show that processed forms Besides facilitating ECM degradation, microvesicles have also been shown to promote the horizontal propagation of oncogenes among subsets of cancer cells [31] . Microvesicles shed from glioblastoma cells have been shown to contain microRNAs in addition to angiogenic factors [32] . Studies also suggest that microvesicles enable the escape of tumors from immune surveillance, thus promoting tumor cell survival [33] . Consistent with these findings, we observed that MHC class I is contained within microvesicles. How cargo is directed to surface-associated vesicles will require further investigation, although it appears that cargo contained and trafficked via ARF6-regulated endosomal pathways, e.g., MHC class I, b1-integrin receptors, and VAMP3 [4] , are delivered to the microvesicles. Microvesicles are devoid of VAMP7 and Rab8, both of which have been implicated in MT1MMP delivery to the cell surface [34, 35] , and also of transferrin receptors, which also traffic through the ARF6 compartment in some cell types (reviewed in [4] ). Thus, cargo appears to be selectively sorted into microvesicles at the cell surface. We suggest that vesicle shedding occurs at specific sites on the plasma membrane and is designed to release selected cellular components into the surrounding environment, particularly those involved in cell-matrix interactions and matrix degradation. Rab8-and VAMP7-dependent MT1MMP delivery to the cell surface likely facilitates pericellular proteolysis.
This study also supports the view that microvesicle release is accompanied by localized lipid scrambling and that vesicle-mediated proteolysis requires the binding of integrin receptors to the ECM [36] . Localized lipid scrambling with PS externalization has also been shown to occur in other nonapoptotic processes such as myotube formation [37] and rapid modulation of the activity of signaling proteins at the surface of nonapoptotic lymphocytes [38] .
Pharmacological inhibition of actin polymerization and myosin function prevents microvesicle release, suggesting that outward fission likely occurs via an actomyosin-based process. We show that ARF6-dependent activation of ERK promotes MLCK phosphorylation and subsequent MLC phosphorylation, thereby facilitating actomyosin-based contraction at vesicle necks, leading to microvesicle release. The intricate rigor of this regulation is manifest in the fact that when ARF6 activation is blocked, not only does ERK activation and ERK-regulated MLCK phosphorylation not ensue, but PKC-mediated phosphorylation and inactivation of MLC also occurs as a consequence (Figure 7) . All of these observations support earlier findings that ARF6-induced ERK activation has a profound effect on tumor cell invasion. ARF6-induced ERK activation is dependent on the accumulation of PA. PA could facilitate ERK recruitment to the cell surface as described above, but may also be required to modify the lipid environment to facilitate the recruitment of components of the ERK cascade such as Raf to the plasma membrane as previously documented [39, 40] .
Invadopodia and microvesicles appear to be distinct structures. Cortactin, a bona fide component of invadopodia, is absent in microvesicles. Although proteases at the invadopodia surface might represent a mechanism for local pericellular proteolysis at the leading/invading membrane edge, microvesicle release likely promotes more distant focal proteolysis and creation of an invasion path. It is possible that some tumor lines may exhibit both invasion mechanisms, whereas in others one of these mechanisms may dominate. The formation of invadopodia and release of microvesicles are both dependent on ARF6-induced ERK activation (Figure 7) .
The shedding of membrane microvesicles is not restricted to pathological conditions and is also observed in normal physiological conditions. For example, microvesicles secreted by skeletal cells enable bone mineralization in vivo, whereas microvesicles secreted by normal endothelial cells have been implicated in angiogenesis [41] . Microvesicles have also been shown to play a role in mRNA transfer in embryonic stem cells and in viral packaging and delivery to the extracellular environment [12, 36, 42] . Thus, in addition to providing strategies for cancer therapeutics and diagnostics, knowledge about the mechanism of microvesicle shedding may shed light on other events requiring plasma membrane budding.
Experimental Procedures Antibodies and Plasmids
The following antibodies were used in this study: anti-neutralizing b1-integrin, AIIB2 (Developmental Studies Hybridoma Bank at the University of Iowa), anti-Rab-8A and anti-Tsk5 (Santa Cruz Biotechnology), anti-MHCclass I (AbD Serotec), anti-HA (Covance), anti-TfnR (Zymed), antibodies against phospho-MLC, phospho-ERK, total ERK, cortactin, and cleaved caspase-3 (Cell Signaling Technology), anti-a-tubulin antibody (SigmaAldrich), and anti-GFP (Roche). The MT1MMP antibody was a gift from M.C. Rio (Institut de Gé né tique et de Biologie Molé culaire et Cellulaire, CNRS/INSERM/ULP, Illkirch, Strasbourg, France). GFP-ERK (Addgene plasmid 14747) was from Addgene [43] . HA-tagged ARF6-N48I was kindly provided by N. Vitale (Centre National de la Recherche Scientifique and Universite Louis Pasteur). Plasmids encoding GFP-VAMP3 and GFP-VAMP7 were a gift from T. Galli (Institut Jacques Monod, Paris).
Cell Culture and Microvesicle Isolation LOX, LOX , and LOX ARF6-GDP cell lines were cultured as described [5] . Cells were seeded in tissue culture flasks at 50% confluency. Media was carefully removed from cells at w80% confluence and centrifuged consecutively at 800 3 g for 10 min, 2,500 3 g for 15 min, and 10,000 3 g for 30 min. Where indicated, this was followed by centrifugation of the supernatant at 100,000 3 g for 1 hr. Isolated microvesicles were washed in phosphate-buffered saline (PBS) and lysed, and protein content was estimated via the Bradford assay (Bio-Rad).
Gelatin Zymography
Microvesicles isolated from the growth media were lysed in RIPA buffer and separated on SDS-PAGE gels containing gelatin to assess gelatinase activity, as previously described [44] .
In Vitro Degradation Assay
The gelatin degradation assay was as previously described [45] . Alternatively, isolated microvesicles were seeded and incubated on gelatin-coated coverslips for 6-8 hr.
Immunofluorescence Staining and Microscopy Cultured cells and/or microvesicles plated on poly-L-lysine-coated or gelatin-coated glass coverslips were fixed and processed as described [5] . F-actin distribution was visualized by staining with rhodamine-phalloidin (Molecular Probes). Labeling of the cell surface with FITC-annexin V was performed with a kit from Beckman Coulter according to the manufacturer's protocol. Cells were fixed and, where indicated, the surface was labeled for b1-integrin (without permeabilization) and processed for immunofluorescence microscopy. Cells were visualized with a Nikon microscope coupled to a Bio-Rad MRC 1024 scanning confocal three-channel system.
Electron Microscopy
Conventional and whole-mount electron microscopy was performed as described [46] . Briefly, cells grown on coverslips were fixed with 2.5% glutaraldehyde in 0.1 M cacodylate buffer overnight and processed as described. For whole-mount membrane preparations, the 100,000 3 g and 10,000 3 g pellets were gently suspended in a small volume of PBS, deposited for 20 min on formvar/carbon-coated EM grids, and processed for EM.
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